ZA200208413B - Formulation having mobilising activity. - Google Patents
Formulation having mobilising activity. Download PDFInfo
- Publication number
- ZA200208413B ZA200208413B ZA200208413A ZA200208413A ZA200208413B ZA 200208413 B ZA200208413 B ZA 200208413B ZA 200208413 A ZA200208413 A ZA 200208413A ZA 200208413 A ZA200208413 A ZA 200208413A ZA 200208413 B ZA200208413 B ZA 200208413B
- Authority
- ZA
- South Africa
- Prior art keywords
- haematopoietic
- progenitors
- capacity
- factor
- csf
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- 238000009472 formulation Methods 0.000 title claims description 20
- 230000001483 mobilizing effect Effects 0.000 title description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 54
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims description 44
- 229960004120 defibrotide Drugs 0.000 claims description 43
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 33
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 33
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 230000004087 circulation Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002123 temporal effect Effects 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002960 bfu-e Anatomy 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00830293A EP1147777A1 (en) | 2000-04-18 | 2000-04-18 | Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200208413B true ZA200208413B (en) | 2003-10-17 |
Family
ID=8175292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200208413A ZA200208413B (en) | 2000-04-18 | 2002-10-17 | Formulation having mobilising activity. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20040131588A1 (sl) |
| EP (3) | EP1147777A1 (sl) |
| JP (1) | JP5205668B2 (sl) |
| KR (1) | KR100849491B1 (sl) |
| CN (1) | CN1183962C (sl) |
| AT (2) | ATE310532T1 (sl) |
| AU (2) | AU5832201A (sl) |
| BG (1) | BG107203A (sl) |
| CA (1) | CA2406179C (sl) |
| CY (1) | CY1104971T1 (sl) |
| CZ (1) | CZ20023426A3 (sl) |
| DE (2) | DE60115222T2 (sl) |
| DK (2) | DK1276497T3 (sl) |
| EE (1) | EE200200596A (sl) |
| ES (2) | ES2252227T3 (sl) |
| HR (1) | HRP20020835A2 (sl) |
| HU (1) | HUP0300560A3 (sl) |
| IL (1) | IL152328A (sl) |
| IS (1) | IS2171B (sl) |
| MX (1) | MXPA02010346A (sl) |
| NO (1) | NO20024988L (sl) |
| NZ (1) | NZ522016A (sl) |
| PL (1) | PL358100A1 (sl) |
| PT (1) | PT1621207E (sl) |
| RO (1) | RO121006B1 (sl) |
| RU (1) | RU2248216C2 (sl) |
| SI (1) | SI21079B (sl) |
| SK (1) | SK14892002A3 (sl) |
| UA (1) | UA73566C2 (sl) |
| WO (1) | WO2001078761A2 (sl) |
| ZA (1) | ZA200208413B (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
| US7417026B2 (en) | 2003-08-13 | 2008-08-26 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
| JP2007535479A (ja) | 2003-08-13 | 2007-12-06 | チルドレンズ ホスピタル メディカル センター | ＧＴＰａｓｅを調節するためのキメラペプチド |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| RU2376985C1 (ru) * | 2008-07-17 | 2009-12-27 | Владислав Николаевич Ласкавый | Средство для активации стволовых клеток |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| ES2660969T5 (es) | 2012-06-22 | 2021-09-03 | Gentium S R L | Método basado en euglobulina para determinar la actividad biológica de defibrotida |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| CN106567694A (zh) * | 2016-11-14 | 2017-04-19 | 北京国泰通源技术有限公司 | 智能控水短节 |
| JP6893999B2 (ja) * | 2018-01-12 | 2021-06-23 | セルミグ、バイオラブズ、インコーポレイテッドＣｅｌｌｍｉｇ Ｂｉｏｌａｂｓ Ｉｎｃ． | 細胞嚢および細胞嚢管の発生方法 |
| KR20220071274A (ko) | 2019-11-13 | 2022-05-31 | 후지필름 가부시키가이샤 | 가식 필름, 성형물, 및 전자 디바이스 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1190313B (it) | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| JP2907447B2 (ja) * | 1988-08-24 | 1999-06-21 | 中外製薬株式会社 | 抗血栓剤 |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| JP3021906B2 (ja) * | 1992-01-28 | 2000-03-15 | 松下電器産業株式会社 | 電動調理機 |
| JPH08127539A (ja) * | 1994-10-31 | 1996-05-21 | Ajinomoto Co Inc | ヒトｉｌ−１１を含有する末梢血幹細胞増加剤 |
| AU3994095A (en) * | 1994-11-30 | 1996-06-19 | Chugai Seiyaku Kabushiki Kaisha | Thrombocytotic factor |
| DE69733694T2 (de) * | 1996-07-10 | 2006-07-06 | Muramatsu, Takashi, Nagoya | Verwendung von proteinen aus der mk familie als hämatopoietischer faktor |
| WO1999026639A1 (en) * | 1997-11-26 | 1999-06-03 | Allegheny University Of The Health Sciences | Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood |
| US6573372B2 (en) * | 1999-01-07 | 2003-06-03 | Heska Corporation | Feline immunoglobulin E molecules and compositions there of |
-
2000
- 2000-04-18 EP EP00830293A patent/EP1147777A1/en not_active Withdrawn
-
2001
- 2001-04-10 ES ES01931582T patent/ES2252227T3/es not_active Expired - Lifetime
- 2001-04-10 EP EP01931582A patent/EP1276497B1/en not_active Expired - Lifetime
- 2001-04-10 CZ CZ20023426A patent/CZ20023426A3/cs unknown
- 2001-04-10 AT AT01931582T patent/ATE310532T1/de active
- 2001-04-10 KR KR1020027013967A patent/KR100849491B1/ko not_active IP Right Cessation
- 2001-04-10 PT PT05108424T patent/PT1621207E/pt unknown
- 2001-04-10 DK DK01931582T patent/DK1276497T3/da active
- 2001-04-10 WO PCT/EP2001/004105 patent/WO2001078761A2/en active IP Right Grant
- 2001-04-10 EP EP05108424A patent/EP1621207B1/en not_active Expired - Lifetime
- 2001-04-10 SI SI200120022A patent/SI21079B/sl not_active IP Right Cessation
- 2001-04-10 CA CA2406179A patent/CA2406179C/en not_active Expired - Fee Related
- 2001-04-10 AT AT05108424T patent/ATE443524T1/de active
- 2001-04-10 DE DE60115222T patent/DE60115222T2/de not_active Expired - Lifetime
- 2001-04-10 RU RU2002130719/15A patent/RU2248216C2/ru not_active IP Right Cessation
- 2001-04-10 RO ROA200201305A patent/RO121006B1/ro unknown
- 2001-04-10 IL IL152328A patent/IL152328A/en active IP Right Grant
- 2001-04-10 AU AU5832201A patent/AU5832201A/xx active Pending
- 2001-04-10 PL PL01358100A patent/PL358100A1/xx not_active Application Discontinuation
- 2001-04-10 SK SK1489-2002A patent/SK14892002A3/sk unknown
- 2001-04-10 CN CNB018082025A patent/CN1183962C/zh not_active Expired - Fee Related
- 2001-04-10 DE DE60140015T patent/DE60140015D1/de not_active Expired - Lifetime
- 2001-04-10 EE EEP200200596A patent/EE200200596A/xx unknown
- 2001-04-10 ES ES05108424T patent/ES2335776T3/es not_active Expired - Lifetime
- 2001-04-10 AU AU2001258322A patent/AU2001258322B2/en not_active Ceased
- 2001-04-10 DK DK05108424.2T patent/DK1621207T3/da active
- 2001-04-10 NZ NZ522016A patent/NZ522016A/en unknown
- 2001-04-10 MX MXPA02010346A patent/MXPA02010346A/es active IP Right Grant
- 2001-04-10 JP JP2001576061A patent/JP5205668B2/ja not_active Expired - Fee Related
- 2001-04-10 HU HU0300560A patent/HUP0300560A3/hu unknown
- 2001-04-10 US US10/432,741 patent/US20040131588A1/en not_active Abandoned
- 2001-10-04 UA UA2002119177A patent/UA73566C2/uk unknown
-
2002
- 2002-10-14 IS IS6581A patent/IS2171B/is unknown
- 2002-10-16 NO NO20024988A patent/NO20024988L/no not_active Application Discontinuation
- 2002-10-17 ZA ZA200208413A patent/ZA200208413B/en unknown
- 2002-10-17 BG BG107203A patent/BG107203A/bg unknown
- 2002-10-18 HR HR20020835A patent/HRP20020835A2/xx not_active Application Discontinuation
-
2006
- 2006-02-08 CY CY20061100179T patent/CY1104971T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9782429B2 (en) | Formulation having mobilizing activity | |
| Grasso et al. | Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? | |
| RU2311921C2 (ru) | Лекарственные средства для лечения ишемических заболеваний | |
| US20070258945A1 (en) | G-GSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction | |
| JP2010280671A (ja) | エリスロポエチンの使用 | |
| JP2001515047A (ja) | コンセンサスインターフェロンを使用する多発性硬化症患者の治療方法 | |
| EP1276497B1 (en) | Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors | |
| AU2001258322A1 (en) | Formulation having mobilising activity | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| WO1997035609A1 (fr) | Inhibiteur de la neoformation de vaisseaux sanguins renfermant un inhibiteur du mecanisme d'action du facteur tissulaire | |
| JPH03503418A (ja) | 哺乳動物におけるリポタンパクコレステロールプロフィール改善のための組成物および用途 | |
| Visani et al. | All‐trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia | |
| EP0950416B1 (en) | Use of TCF-II for the treatment of cancer related body weight loss, anaemia and TNF elevation | |
| Okada et al. | Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure | |
| EP1036566B1 (en) | Preparation for continuous intravenous administration | |
| CN116790744B (zh) | 一种缺血性心脏病晚期纤维化干预靶点及其应用 | |
| JP4790195B2 (ja) | 組織再生剤 | |
| JP2010539136A (ja) | 卒中発作を治療するためのｇ−ｃｓｆの使用 | |
| Carrión et al. | A randomised study of 10? µg/kg/day (single dose) vs 2× 5? µg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients. |